

Glenmark Life Sciences Limited - Disclosure of Related Party Transactions for the half year ended 30th September 2024

(Amounts in Rs. Millions)

Sr. No.	Details of the party entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other Related Party Transactions	Value of the related party transaction as approved by the audit committee (Refer Note 6)	Remark on approval by Audit Committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once during the reporting period when such transaction was undertaken.						
													In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
1	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Inc., USA		Refer Note 1	Sale of goods or services	500	-	138.50	306.25	183.42								
2	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Ltd., India		Refer Note 1	Purchase of goods or services	225	-	68.42	-	-								
3	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Ltd., India		Refer Note 1	Sale of goods or services	10,000	-	3,751.98	2,843.14	3,918.49								
4	Glenmark Life Sciences Limited		Aculife Healthcare Private Limited		Fellow Subsidiary	Sale of goods or services	2	-	0.39	-	-								
5	Glenmark Life Sciences Limited		Viso Farmaceutica S.L.U.		Refer Note 1	Purchase of goods or services	35	-	16.78	-2.10	-19.40								
6	Glenmark Life Sciences Limited		Glenmark Farmaceutica Ltda., Brazil		Refer Note 1	Purchase of goods or services	80	-	34.06	-26.39	-45.09								
7	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Inc., USA		Refer Note 1	Any other transaction		-	15.90	-	-								
8	Glenmark Life Sciences Limited		Glenmark Pharmaceuticals Europe Ltd., U.K.		Refer Note 1	Any other transaction		-	-	-0.38	-8.11								
9	Glenmark Life Sciences Limited		Dr. Yasir Rawjee		Managing Director & CEO	Remuneration		-	52.19	-	-								
10	Glenmark Life Sciences Limited		Mr. Tushar Mistry		Chief Financial Officer	Remuneration		-	12.42	-	-								
11	Glenmark Life Sciences Limited		Mr. Rudalf Corriea		Company Secretary & Compliance Officer	Remuneration		-	1.61	-	-								
12	Glenmark Life Sciences Limited		Mr. Vinod Naik		Executive Director & Head of the Technical Operations	Remuneration		-	17.81	-	-								
13	Glenmark Life Sciences Limited		Mrs. Manju Agarwal		Non-executive Director	Any other transaction		-	0.70	-	-								
14	Glenmark Life Sciences Limited		Mr. T L Easwar		Non-executive Director	Any other transaction		-	0.50	-	-								
15	Glenmark Life Sciences Limited		Mr. Kaushikbhai Patel		Non-executive Director	Any other transaction		-	0.90	-	-								
16	Glenmark Life Sciences Limited		Mr. Vijaykumar Shah		Non-executive Director	Any other transaction		-	0.50	-	-								
17	Glenmark Life Sciences Limited		Mr. Savan Godiawala*		Non-executive Director	Any other transaction		-	0.40	-	-								

Notes:

- Glenmark Pharmaceuticals Limited (GPL) sold 75 percent stake of the Company to Nirma Limited pursuant to Share Purchase Agreement dated 21st September, 2023 and ceased to be holding company with effect from 6th March, 2024, however, GPL and its affiliates will be considered as related party for the Company pursuant to regulation 2(1)(zb) of SEBI (LODR) Regulations, 2015 which mandates any entity to be considered as related party where such entity is holding more than of ten per cent or more, at any time, during the immediate preceding financial year.
- Expenses for Defined Benefit Plans and Compensated Absences are provided on actuarial basis for the Company as a whole, the amounts pertaining to Key Managerial Personnel is not included.
- Share Based Payment Expenses pertaining to Key Managerial Personnel is not included.
- Balances have been aggregated entity wise for all type of transactions and shown as net receivable/(payable)
- RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.
- The value of the related party transaction denotes the amount approved by the Audit Committee for financial year 2024-25 except for Glenmark Pharmaceuticals Limited where the same was approved by the Audit Committee, Board of Directors, Shareholders of the Company for period October 23 to September 2024.
- * Appointed with effect from 25/04/2024